TSTO Reports: A Variant source Capture of the Tetrasilver Tetroxide Dossier

What this capture is

This page records a source dossier capture identified by the native source filename [source note 3]. The underlying page belongs to the TSTOReports.html family — the source archive aggregation of reports and patent material concerning tetrasilver tetroxide (Ag₄O₄, also written TSTO), the mixed-valence silver oxide associated with Marvin S. Antelman.

It is a variant capture, not a new discovery. Several sibling captures of the same page family already exist in this wiki, including Tetrasilver Tetroxide (TSTO): The source archive Sales-and-Patent Dossier, Tetrasilver Tetroxide: A Third source Capture (Variant Record), Tetrasilver Tetroxide: The Electron-Jumping Claim, the Patent Set and the Negative Kinshasa Result and TSTO Preparation Page: A source Capture Without Body Content (611cac2aeb905f5f). Readers looking for the substantive treatment of the chemistry, the sales framing and the patent record should treat those pages and the entity/concept pages they link to as the primary account; this page exists to keep the capture record complete and to note what this particular variant does and does not add.

Subject: tetrasilver tetroxide

Tetrasilver tetroxide is a silver oxide in which silver appears in two oxidation states within a single lattice — formally Ag(I) and Ag(III) — giving the compound its alternative name Silver(I,III) Oxide and its classification as a Mixed-Valence Silver Oxide. The dossier's central product claim is that this mixed-valence structure behaves as an Electron Jumping Compound / Molecular Battery Claim: a "molecular battery" in which electrons shuttle between the Ag(I) and Ag(III) centres, with the redox cycling releasing silver ions into the surrounding medium.

That release is the basis for the applications the dossier advertises, principally Water Disinfection by Silver and broader antimicrobial use, which sit inside the well-documented Antimicrobial Silver and the Oligodynamic Effect literature. The source archive material presents these as inventor claims and patent-backed product descriptions rather than as results from controlled studies.

How the dossier is organized

The TSTOReports.html page family is a report-and-patent aggregation. Its contents are of the kind typical of the source archive dossiers on a single substance:

• collected reports and reprinted commentary on the compound;
• patent references covering preparation and application;
• promotional or sales framing for TSTO-based products;
• a small set of image assets, including the file referenced in the capture audit as tetrasilver.jpg (see TetraSilver TetrOxide Information: The Lattice Diagram and the Two-Part Mechanism Claim).

The capture audit for this variant records only a small number of health/biology topic hits and a low estimated probability of a capture problem, which is consistent with a page body that is present but thin on quantitative scientific content. The capture does include reported measurements from two Panminerva Med pilot registry abstracts (e.g., 148 patients; complete ulcer closure 42% vs 22%, P=<0.05) and a Future Microbiol review, plus dated news items (VOA, 2007/2009). These are reported results from the dossier's own cited studies, not independent replication or controlled trials establishing efficacy.

Claims attributed to the dossier

The following are the dossier's assertions, recorded here as claims and not as validated findings:

1. Identity. TSTO is a mixed-valence silver oxide, Ag₄O₄, containing Ag(I) and Ag(III) centres.
2. Mechanism. It acts as an "electron jumping compound" or molecular battery, releasing silver ions through internal redox cycling.
3. Applications. Claimed uses include water disinfection and antimicrobial treatment.

The mechanism claim is the point of tension. Mixed-valence silver oxides are ordinary inorganic chemistry; the "molecular battery" language is a framing device layered on top of a conventional redox description. Nothing in this capture supplies an energy balance, a measured ion-release rate, or a comparison against simpler silver salts that would distinguish the framing from standard silver-ion antimicrobial action.

Evidence status and limitations

• Provenance is patent-and-report, not experimental. The dossier aggregates patent material and secondary reports. Under the wiki's standing caution on Patent as Evidence, the presence of a patent or a product description is not proof of efficacy.
• No independent validation appears in this capture. There is no indication of controlled trials, replication, or third-party measurement.
• Preparation detail is not resolved here. The wiki's Tetrasilver Tetroxide Preparation (Unresolved in This Capture) page is currently flagged as unresolved in the earlier captures. This variant does not evidence preparation steps that would close that gap; the gap should be treated as persisting rather than papered over.
• Capture integrity. The audit's low capture-problem probability suggests the body is largely present, but the page may still function as a link and report index rather than substantive text. No content has been invented to fill it.

Relationship to existing wiki pages

This capture reinforces, rather than extends, the existing TSTO material:

• Tetrasilver Tetroxide (Ag₄O₄) — the compound entity page; this capture is an additional source reference for it.
• Marvin S. Antelman — the chemist associated with the TSTO applications.
• Silver(I,III) Oxide and Mixed-Valence Silver Oxide — the formal name and the structural classification.
• Electron Jumping Compound / Molecular Battery Claim — the "molecular battery" mechanism claim.
• Water Disinfection by Silver and Antimicrobial Silver and the Oligodynamic Effect — the application context.
• Tetrasilver Tetroxide: The Electron-Jumping Claim, the Patent Set and the Bounded Evidence — the evidence ledger, to which this capture's claims belong.
• the source archive — the hosting archive.

Medical and safety note

Any antimicrobial or disinfection claim in this dossier is recorded as a research and inventor account. Nothing here is treatment guidance, and no dosing or self-administration information is provided or implied.